Abstract Number: 1314 • ACR Convergence 2021
Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease mainly affecting sacroiliac joints and spine. Peripheral arthritis, dactylitis and enthesitis may also occur. Acute…Abstract Number: 1787 • ACR Convergence 2021
What Is Peripheral SpondyloArthritis? Identifying Disease Phenotype and Burden: A Post Hoc Analysis of the ASAS-PerSpA International Study
Background/Purpose: Peripheral spondyloarthritis (pSpA) shows features that overlap with psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and other forms of SpA and is unsatisfactorily defined despite…Abstract Number: 0059 • ACR Convergence 2021
Deep Immune Cell Profiling of Tissue Microenvironment Using Imaging Mass Cytometry in Psoriatic Disease
Background/Purpose: Cross talk between different cell types, such as T cell subsets and other immune cell populations, is important in psoriatic disease. Imaging Mass Cytometry…Abstract Number: 0366 • ACR Convergence 2021
Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS)
Background/Purpose: AxSpA is associated with substantial negative consequences regarding work status and career prospects. The aim is to identify factors associated with barriers to job…Abstract Number: 0384 • ACR Convergence 2021
A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio
Background/Purpose: Biomarkers of disease activity/severity and imaging outcomes in axial spondyloarthritis (axSpA) remain a challenge. The most common relevant biomarker is the C-Reactive Protein (CRP),…Abstract Number: 0907 • ACR Convergence 2021
Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients with Non-Radiographic Axial Apondyloarthritis
Background/Purpose: In two years, approximately 10% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) progresses to ankylosing spondylitis (AS). There are no data available of more…Abstract Number: 0936 • ACR Convergence 2021
Factors Associated with the Development of Anti-drug Antibodies to Tumour Necrosis Factor Inhibitors in Patients with Axial Spondyloarthritis; A Two Year Follow-up Study
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting sacroiliac joints and spine as well as peripheral joints and entheses. Tumour necrosis factor…Abstract Number: 1316 • ACR Convergence 2021
Vitamin D Deficiency and Disease Activity in Patients with Spondyloarthritis
Background/Purpose: There are increasing data about vitamin D immunomodulatory potential in different rheumatologic disorders. Deficiency of vitamin D is frequent in patients with spondyloarthritis (SpA)…Abstract Number: 1788 • ACR Convergence 2021
Improving Care and Capacity Through Capturing and Recording Patient Reported Outcomes with Digital Solutions in Spondyloarthritis
Background/Purpose: Patient-reported outcomes (PROs) have always been at the forefront for the assessment of spondyloarthritis (SpA) which includes axial Spa (axSpA) and psoriatic arthritis (PsA).…Abstract Number: 0062 • ACR Convergence 2021
Axial Spondyloarthritis and Its Related Immune-Mediated Diseases Share a Gut Microbiome Signature Besides Their Own Distinctive Profile
Background/Purpose: Deep profiling of gut microbiota may reveal new pathways of how SpA and its related diseases such as Crohn’s disease (CD) and acute anterior…Abstract Number: 0367 • ACR Convergence 2021
Can Belonging to an AxSpA Patient Organization Be Associated with Benefits to Its Members? Results from the European Map of Axial Spondyloarthritis (EMAS)
Background/Purpose: Patient organizations (POs) provide education and support services aimed to improve the quality of life of axSpA patients. This analysis aims to identify factors…Abstract Number: 0450 • ACR Convergence 2021
Identifying Trajectories of Radiographic Spinal Disease in Ankylosing Spondylitis
Background/Purpose: Little is known about the natural history of spinal disease in Ankylosing Spondylitis (AS). Our objective was to identify distinct patterns of change in…Abstract Number: 0910 • ACR Convergence 2021
The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort
Background/Purpose: Ankylosing spondylitis (AS) is associated with greater cardiovascular (CV) risk than in the general population. The impact of tumor necrosis factor inhibitors (TNFi) on…Abstract Number: 0938 • ACR Convergence 2021
Comparative Effectiveness and Treatment Survival of Different TNF Inhibitors for Axial Spondyloarthritis in Real-World Clinical Practice
Background/Purpose: Tumor necrosis factor (TNF) inhibitors are the mainstay treatment for NSAID refractory axial spondyloarthritis (axSpA). However, few data exist on their use during routine…Abstract Number: 1317 • ACR Convergence 2021
Impairment of Memory in Axial Spondyloarthritis?
Background/Purpose: There is certain evidence that neuropsychiatric changes occur in systemic lupus(1) and rheumatoid arthritis (2). However, there is little knowledge about possible cognitive changes…
- « Previous Page
- 1
- …
- 27
- 28
- 29
- 30
- 31
- …
- 41
- Next Page »